Silverback Therapeutics, Inc.

Silverback Therapeutics, Inc.

SBTX

SBTXSilverback Therapeutics, Inc. US flag

NASDAQ Global Market

5.87

USD

+0.06

- -

550.43MMarket Cap

CIK

0001671858

ISIN

US82835W1080

CUSIP

82835W108

Return %

Stock

S&P500

1Y

38.44

26.53

3Y

-76.52

76.60

5Y

-76.52

80.11

Use logarithmic scale

No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Company Description

CEO: Peter A. Thompson
Full Time Employees: 90
Sector: Healthcare
Industry: Biotechnology
Address: 500 Fairview Avenue North Seattle WA United States of America 98109
IPO Date: Dec 3, 2020
CIK: 0001671858
Website: silverbacktx.com
Similar Companies: Promore Pharma AB (publ) (PROMO.ST)
Great Novel Therapeutics Biotech & Medicals (7427.TWO)
Photocure ASA (0IMT.L)
Heidelberg Pharma AG (HPHA.DE)
Formycon AG (FYB.DE)
immatics biotechnologies GmbH (IMTXW)
Business: Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of targeted immunotherapies for cancer and serious diseases. The company focuses on its proprietary ImmunoTAC platform, which enables the strategic pairing of linker-payloads with monoclonal antibodies to modulate disease-modifying pathways and deliver tissue-targeted therapeutics. Core products include immuno-oncology agents such as SBTX-101, an investigational therapy for solid tumors in Phase 1 clinical trials, as well as preclinical candidates SBTX-102 and SBTX-103 targeting breast and prostate cancers, respectively. Silverback also explores autoimmune disease treatments under its pipeline. Headquartered in Seattle, Washington, the company operates primarily in the U.S. market. In a major strategic development, Silverback Therapeutics merged with ARS Pharmaceuticals in an all-stock transaction completed in late 2022, after which the combined entity was renamed ARS Pharmaceuticals, Inc., and trades under the ticker SPRY. This merger brought significant capital of over $265 million to support the potential launch of neffy®, an intranasal epinephrine nasal spray for severe allergic reactions, currently under FDA review with a pending PDUFA date in 2023. Following this merger, Silverback shifted its strategic focus to the development and commercialization of neffy® alongside advancing its immunotherapy pipeline. Additionally, it discontinued previous oncology programs SBT6050 and SBT6290 and streamlined operations with a workforce reduction to extend its cash runway into the second half of 2026. The consolidated company now prioritizes both allergy treatment commercialization and its immuno-oncology development programs. Silverback operates principally in biotechnology research and development with a niche in immuno-oncology and immunology therapeutic areas. It partners strategically to enhance drug development and commercialization efforts. Founded in 2008, the company has built a strong portfolio leveraging its ImmunoTAC technology platform for systemic and targeted delivery of immune-modulating therapeutics, targeting primarily cancer and autoimmune disorders. Its recent merger and pivot towards allergy treatment mark significant shifts in the company’s operational and strategic trajectory. The company’s commercial and R&D activities span the U.S. pharmaceutical and biotechnology markets.

Company News